ストックスクリーナーアプリを入手
175.75
1.27%
-2.335
Charles River Laboratories International Inc (CRL) 最新ニュース
Charles River Labs stock target cut, hold rating on expected decline - Investing.com
Charles River Laboratories International (NYSE:CRL) Reaches New 1-Year LowHere's Why - MarketBeat
Citi flags revenue and margin headwinds for Charles River Labs shares By Investing.com - Investing.com South Africa
Charles River Seeks Strategic Acquisitions - Marketscreener.com
Charles River Labs stock hits 52-week low at $176.34 By Investing.com - Investing.com Australia
Charles River Laboratories International's (CRL) "Outperform" Rating Reiterated at William Blair - MarketBeat
BofA keeps Charles River Labs stock at Neutral on challenges By Investing.com - Investing.com Canada
TD Cowen cautious on Charles River Labs stock as 2025 guide signals further declines - Investing.com India
JPMorgan maintains Charles River Labs stock at Neutral on challenges - Investing.com India
Citi flags revenue and margin headwinds for Charles River Labs shares - Investing.com India
Charles River Laboratories International (NYSE:CRL) Shares Gap DownWhat's Next? - MarketBeat
JPMorgan maintains Charles River Labs stock at Neutral on challenges By Investing.com - Investing.com Nigeria
Clinical Trials Support Services Market Poised for Notable Expansion by 2030, Driven by Substantial Investments in R&D from Pharmaceutical and Biopharmaceutical Companies - GlobeNewswire Inc.
Charles River Laboratories (CRL) Provides Preliminary 2025 Finan - GuruFocus.com
Charles River falls after projecting 2025 revenue drop - MSN
Charles River Labs stock hits 52-week low at $176.34 - Investing.com India
Charles River stock falls on 2025 revenue drop (CRL:NYSE) - Seeking Alpha
Charles River Labs Discusses 2025 Financial Outlook - TipRanks
Charles River Laboratories stock falls on weak 2025 revenue outlook By Investing.com - Investing.com UK
Bioanalytical Testing Services Market Size, Embracing Growth - openPR
Charles River Laboratories International Inc. stock outperforms competitors on strong trading day - MarketWatch
Reinhart Partners LLC. Sells 11,822 Shares of Charles River Laboratories International, Inc. (NYSE:CRL) - MarketBeat
Charles River Laboratories to Present at J.P. Morgan Healthcare Conference - sharewise
Charles River Labs to Present Strategic Overview at J.P. Morgan Healthcare Conference - StockTitan
Charles River Laboratories International, Inc. (NYSE:CRL) Receives Consensus Recommendation of "Reduce" from Analysts - MarketBeat
First Hawaiian Bank Reduces Position in Charles River Laboratories International, Inc. (NYSE:CRL) - MarketBeat
Charles River Laboratories International Inc. stock outperforms competitors despite losses on the day - MarketWatch
What Charles River Laboratories International, Inc.'s (NYSE:CRL) P/E Is Not Telling You - Simply Wall St
Charles River Laboratories International Inc. stock underperforms Tuesday when compared to competitors despite daily gains - MarketWatch
Deciphex Secures $32.3M Series C to Transform AI-Powered Pathology Diagnosis - StockTitan
Preclinical Medical Device Testing Services Market Outlook, - GlobeNewswire
Preclinical Medical Device Testing Services Market Outlook, 2025-2035Dominated by Charles River Laboratories Int'l, Eurofins Scientific, SGS, WuXi AppTec, and Pace Analytical Services - Yahoo Finance
Charles River Laboratories International, Inc. (NYSE:CRL) Shares Purchased by JPMorgan Chase & Co. - MarketBeat
Should You Retain Charles River Stock in Your Portfolio Now? - MSN
CHARLES RIVER LABORATORIES SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KAHN SWICK & FOTI, LLC REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Ag - AccessWire
Charles River Laboratories Stock: Is CRL Underperforming the Healthcare Sector? - MSN
Charles River Laboratories Stock: Is CRL Underperforming The Healthcare Sector? - Barchart
Zacks Research Issues Negative Forecast for CRL Earnings - MarketBeat
Charles River Laboratories International Inc. stock underperforms Thursday when compared to competitors despite daily gains - MarketWatch
Declining Stock and Solid Fundamentals: Is The Market Wrong About Charles River Laboratories International, Inc. (NYSE:CRL)? - Simply Wall St
RNA Therapy Clinical Trials Market Top Companies StudyIQVIA; - openPR
Charles River Laboratories International Inc. stock rises Tuesday, still underperforms market - MarketWatch
Charles River Laboratories International Inc. stock underperforms Thursday when compared to competitors - MarketWatch
Interesting CRL Put And Call Options For August 2025 - Nasdaq
Earnings are growing at Charles River Laboratories International (NYSE:CRL) but shareholders still don't like its prospects - Yahoo Finance
Charles River Laboratories International, Inc. (NYSE:CRL) Receives $214.00 Average Price Target from Brokerages - MarketBeat
0.97%
大文字化:
|
ボリューム (24 時間):